Restylane Kysse for Lip Filler
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate how well Restylane Kysse, a lip filler made from hyaluronic acid, improves the appearance of lips in individuals of full Chinese descent. Participants interested in lip augmentation may be suitable candidates. Eligible individuals must be adults with both parents of Chinese descent and an interest in enhancing their lips. Those who have undergone facial surgery or received certain facial fillers in the past year may not qualify. As an unphased trial, this study offers participants the chance to contribute to research that could expand cosmetic options for individuals of Chinese descent.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What is the safety track record for Restylane Kysse?
Research has shown that Restylane Kysse is generally safe for lip enhancement. Studies have found no major safety issues with its use. Most side effects are mild, such as swelling or redness at the injection site, and these usually resolve quickly.
However, the safety of Restylane Kysse during pregnancy, while planning to become pregnant, or while breastfeeding remains unknown. Additionally, studies have not confirmed its safety for use in areas other than the lips and nearby skin lines.
Overall, evidence suggests that Restylane Kysse is well-tolerated for its approved use in enhancing the lips.12345Why are researchers enthusiastic about this study treatment?
Restylane Kysse is unique because it features a specialized form of hyaluronic acid designed specifically for lip enhancement. Unlike other lip fillers, Restylane Kysse uses XpresHAn Technology™, which allows the filler to integrate more naturally into the tissue, offering a softer and more flexible feel. This not only enhances the natural movement of the lips but also provides longer-lasting results with potentially fewer injections compared to traditional fillers. Researchers are excited about Restylane Kysse because it promises a natural look and feel, while also extending the durability of the lip enhancement.
What is the effectiveness track record for Restylane Kysse as a lip filler?
Research has shown that Restylane Kysse, the treatment under study in this trial, effectively enhances lip fullness. In one study, 98% of participants were satisfied with the feel of their lips after treatment. Another study found an immediate increase in lip size following the procedure. After 12 months, about 25% of participants still noticed fuller lips, and over 39% observed a clear improvement even after a year. These findings suggest that Restylane Kysse can provide long-lasting and natural-looking results for lip enhancement.56789
Who Is on the Research Team?
Study Director
Principal Investigator
Galderma R&D
Are You a Good Fit for This Trial?
This trial is for adults over 22, of full Chinese descent, who want lip augmentation and can understand English. They must be willing to follow the study rules and not be pregnant or breastfeeding. People with allergies to hyaluronic acid or certain proteins, recent facial procedures, permanent facial treatments, or those in another study within the last month cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Restylane Kysse for lip augmentation
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Restylane Kysse
Find a Clinic Near You
Who Is Running the Clinical Trial?
Q-Med AB
Lead Sponsor
Doug Caro
Q-Med AB
Chief Executive Officer
Economics degree from Florida State University
Dr. Johan Färnstrand
Q-Med AB
Chief Medical Officer
MD from Uppsala University
Galderma R&D
Lead Sponsor
Flemming Ørnskov
Galderma R&D
Chief Executive Officer since 2019
MD, MPH
Baldo Scassellati Sforzolini
Galderma R&D
Chief Medical Officer
MD, PhD